Seroprevalence and vaccination coverage of vaccine-preventable diseases in perinatally HIV-1-infected patients

Human Vaccines and Immunotherapeutics

Volumn 11, Issue 1, 2015, Pages 263-269

  Sticchi, Laura ^a,b   Bruzzone, Bianca ^b   Caligiuri, Patrizia ^a   Rappazzo, Emanuela ^a   Casto, Michele Lo ^b   De Hoffer, Laura ^b   Gustinetti, Giulia ^b   Viscoli, Claudio ^a,b   Di Biagio, Antonio ^b  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

Author keywords

HIV; Immunization coverage; Routine immunization; Seroprevalence; Vaccination; Vaccine preventable diseases

Indexed keywords

BACTERIUM ANTIBODY; HEPATITIS ANTIBODY;

ADOLESCENT; ADULT; BLOOD; CHILD; COMPLICATION; CROSS-SECTIONAL STUDY; DIPHTHERIA; ENZYME LINKED IMMUNOSORBENT ASSAY; EPIDEMIOLOGY; FEMALE; HEPATITIS A; HEPATITIS B; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; MALE; POLIOMYELITIS; SERODIAGNOSIS; STATISTICS AND NUMERICAL DATA; TETANUS; VACCINATION; YOUNG ADULT;

ADOLESCENT; ADULT; ANTIBODIES, BACTERIAL; CHILD; CROSS-SECTIONAL STUDIES; DIPHTHERIA; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HEPATITIS A; HEPATITIS ANTIBODIES; HEPATITIS B; HIV INFECTIONS; HUMANS; MALE; NEUTRALIZATION TESTS; POLIOMYELITIS; SEROEPIDEMIOLOGIC STUDIES; TETANUS; VACCINATION; YOUNG ADULT;

EID: 84949126533     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.36162     Document Type: Conference Paper

References (30)

1. Bousfiha A, Picard C, Boisson-Dupuis S, Zhang SY, Bustamante J, Puel A, Jouanguy E, Ailal F, El-Baghdadi J, Abel L, et al. Primary immunodeficiencies of protective immunity to primary infections. Clin Immunol 2010; 135:204-9; PMID:20236864; http://dx.doi.org/10.1016/j.clim.2010.02.001
2. Fiore AE, Shay DK, Broder K, Iskander JK, Uyeki TM, Mootrey G, Bresee JS, Cox NS; Centers for Disease Control and Prevention (CDC); Advisory Committee on Immunization Practices (ACIP). Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2008. MMWR Recomm Rep 2008; 57(RR-7):1-60; PMID:18685555
3. Moss WJ, Clements CJ, Halsey NA. Immunization of children at risk of infection with human immunodeficiency virus. Bull World Health Organ 2003; 81:61-70; PMID:12640478
4. Levin MJ. Varicella vaccination of immunocompromised children. J Infect Dis 2008; 197(Suppl 2):S200-6; PMID:18419398; http://dx.doi.org/10.1086/522133
5. Menson EN, Mellado MJ, Bamford A, Castelli G, Duiculescu D, Marczyńska M, Navarro M, Scherpbier HJ, Heath PT; Paediatric European Network for Treatment of AIDS (PENTA) Vaccines Group; PENTA Steering Committee; Children's HIV Association (CHIVA). Guidance on vaccination of HIV-infected children in Europe. HIV Med 2012; 13:333-6, e1-14; PMID:22296225; http://dx.doi.org/10.1111/j.1468-1293.2011.00982.x
6. Rubin LG, Levin MJ, Ljungman P, Davies EG, Avery R, Tomblyn M, Bousvaros A, Dhanireddy S, Sung L, Keyserling H, et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis 2014; 58:309-18; PMID:24421306; http://dx.doi.org/10.1093/cid/cit816
7. Italian Ministry of Health. Piano Nazionale in Prevenzione Vaccinale 2012-14. Available at: http://www.salute.gov.it/imgs/c-17-pubblicazioni-1721-allegato.pdf (accessed on 06/07/2014)
8. Italian Ministry of Health. Linee Guida Italiane sull'utilizzo dei farmaci antiretrovirali e sulla gestione diagnostico-clinica delle persone con infezione da HIV-1 (November 2013). Available at: http://www.salute.gov.it/imgs/C-17-pubblicazioni-2074-allegato.pdf (accessed on 06/07/2014)
9. Geretti AM, Doyle T. Immunization for HIV-positive individuals. Curr Opin Infect Dis 2010; 23:32-8; PMID:19949327; http://dx.doi.org/10.1097/QCO.0b013e328334fec4
10. Myers C, Posfay-Barbe KM, Aebi C, Cheseaux JJ, Kind C, Rudin C, Nadal D, Siegrist CA; Pediatric Infectious Disease Group of Switzerland (PIGS); Swiss Mother and Child HIV Cohort Study (MoCHIV). Determinants of vaccine immunity in the cohort of human immunodeficiency virusinfected children living in Switzerland. Pediatr Infect Dis J 2009; 28:996-1001; PMID:19820427; http://dx.doi.org/10.1097/INF.0b013e3181a78348
11. Fernández-Ibieta M, Ramos-Amador JT, Auñón-Martín I. HIV-infected children vaccination coverage and safety in a Western European cohort: a retrospective study. Int J STD AIDS 2007; 18:351-3; PMID:17524201; http://dx.doi. org/10.1258/095646207780749763
12. th Annual Meeting of the European Society for Paediatric Infectious Disease. Brussels, Belgium, June 2009. [Abstract P227]. Pediatr Infect Dis J 2009; 28:e79
13. Cagigi A, Cotugno N, Giaquinto C, Nicolosi L, Bernardi S, Rossi P, Douagi I, Palma P. Immune reconstitution and vaccination outcome in HIV-1 infected children: present knowledge and future directions. Hum Vaccin Immunother 2012; 8:1784-94; PMID:22906931; http://dx.doi.org/10.4161/hv.21827
14. Plotkin SA. Correlates of protection induced by vaccination. Clin Vaccine Immunol 2010; 17:1055-65; PMID:20463105; http://dx.doi.org/10.1128/CVI.00131-10
15. th Edition.2004. Geneva, Switzerland.
16. Herremans MM, Reimerink JH, Ras A, Van Der Avoort HG, Kimman TG, Van Loon AM, Conyn-Van Spaendonck MA, Koopmans MP. Evaluation of a poliovirus-binding inhibition assay as an alternative to the virus neutralization test. Clin Diagn Lab Immunol 1997; 4:659-64; PMID:9384285
17. Pandolfi E, Carloni E, Marino MG, Ciofi degli Atti ML, Gesualdo F, Romano M, Giannattasio A, Guarino A, Carloni R, Borgia P, et al. Immunization coverage and timeliness of vaccination in Italian children with chronic diseases. Vaccine 2012; 30:5172-8; PMID:21414380; http://dx.doi.org/10.1016/j.vaccine.2011.02.099
18. Mphahlele MJ, Mda S. Immunising the HIV-infected child: a view from sub-Saharan Africa. Vaccine 2012; 30(Suppl 3):C61-5; PMID:22939024; http://dx.doi.org/10.1016/j.vaccine.2012.02.040
19. Moss WJ, Clements CJ, Halsey NA. Immunization of children at risk of infection with human immunodeficiency virus. Bull World Health Organ 2003; 81:61-70; PMID:12640478
20. Pensieroso S, Cagigi A, Palma P, Nilsson A, Capponi C, Freda E, Bernardi S, Thorstensson R, Chiodi F, Rossi P. Timing of HAART defines the integrity of memory B cells and the longevity of humoral responses in HIV-1 vertically-infected children. Proc Natl Acad Sci U S A 2009; 106:7939-44; PMID:19416836; http://dx.doi.org/10.1073/pnas.0901702106
21. Moir S, Buckner CM, Ho J, Wang W, Chen J, Waldner AJ, Posada JG, Kardava L, O'Shea MA, Kottilil S, et al. B cells in early and chronic HIV infection: evidence for preservation of immune function associated with early initiation of antiretroviral therapy. Blood 2010; 116:5571-9; PMID:20837780; http://dx.doi.org/10.1182/blood-2010-05-285528
22. An earlier start for HIV therapy. Nat Med 2009; 15:848; PMID:19661988; http://dx.doi.org/10.1038/nm0809-848
23. Siriaksorn S, Puthanakit T, Sirisanthana T, Sirisanthana V. Prevalence of protective antibody against hepatitis B virus in HIV-infected children with immune recovery after highly active antiretroviral therapy. Vaccine 2006; 24:3095-9; PMID:16488516; http://dx.doi.org/10.1016/j.vaccine.2006.01.045
24. Bekker V, Scherpbier H, Pajkrt D, Jurriaans S, Zaaijer H, Kuijpers TW. Persistent humoral immune defect in highly active antiretroviral therapy-treated children with HIV-1 infection: loss of specific antibodies against attenuated vaccine strains and natural viral infection. Pediatrics 2006; 118:e315-22; PMID:16847077; http://dx.doi.org/10.1542/peds.2005-2616
25. Abzug MJ, Song LY, Fenton T, Nachman SA, Levin MJ, Rosenblatt HM, Pelton SI, Borkowsky W, Edwards KM, Peters J; International Maternal Pediatric Adolescent AIDS Clinical Trials Group P1024 Protocol Team. Pertussis booster vaccination in HIV-infected children receiving highly active antiretroviral therapy. Pediatrics 2007; 120:e1190-202; PMID:17938165; http://dx.doi.org/10.1542/peds.2007-0729
26. Madhi SA, Klugman KP, Kuwanda L, Cutland C, Käyhty H, Adrian P. Quantitative and qualitative anamnestic immune responses to pneumococcal conjugate vaccine in HIV-infected and HIV-uninfected children 5 years after vaccination. J Infect Dis 2009; 199:1168-76; PMID:19265481; http://dx.doi.org/10.1086/597388
27. Thakur A, Pedersen LE, Jungersen G. Immune markers and correlates of protection for vaccine induced immune responses. Vaccine 2012; 30:4907-20; PMID:22658928; http://dx.doi.org/10.1016/j.vaccine.2012.05.049
28. Tejiokem MC, Gouandjika I, Béniguel L, Zanga MC, Tene G, Gody JC, Njamkepo E, Kfutwah A, Penda I, Bilong C, et al. HIV-infected children living in Central Africa have low persistence of antibodies to vaccines used in the Expanded Program on Immunization. PLoS One 2007; 2:e1260; PMID:18060056; http://dx.doi.org/10.1371/journal.pone.0001260
29. Sutter RW, Suleiman AJ, Malankar P, Al-Khusaiby S, Mehta F, Clements GB, Pallansch MA, Robertson SE. Trial of a supplemental dose of four poliovirus vaccines. N Engl J Med 2000; 343:767-73; PMID:10984564; http://dx.doi.org/10.1056/NEJM200009143431103
30. Triki H, Abdallah MV, Ben Aissa R, Bouratbine A, Ben Ali Kacem M, Bouraoui S, Koubaa C, Zouari S, Mohsni E, Crainic R, et al. Influence of host related factors on the antibody response to trivalent oral polio vaccine in Tunisian infants. Vaccine 1997; 15:1123-9; PMID:9269056; http://dx.doi.org/10.1016/S0264-410X(97)00001-7